Compare CIM & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CIM | MLTX |
|---|---|---|
| Founded | 2007 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 863.0M |
| IPO Year | 2007 | 2020 |
| Metric | CIM | MLTX |
|---|---|---|
| Price | $8.42 | $11.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 15 |
| Target Price | $14.17 | ★ $28.54 |
| AVG Volume (30 Days) | 1.6M | ★ 1.8M |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | ★ 21.30% | N/A |
| EPS Growth | ★ 56.36 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.11 | $9.37 |
| 52 Week High | $14.18 | $23.29 |
| Indicator | CIM | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 27.87 | 52.60 |
| Support Level | N/A | $9.73 |
| Resistance Level | $13.82 | $19.32 |
| Average True Range (ATR) | 0.26 | 0.74 |
| MACD | 0.03 | 0.30 |
| Stochastic Oscillator | 24.79 | 61.95 |
Chimera Investment Corporation is an internally managed REIT whose principal business objective is to provide attractive risk-adjusted returns and distributable income through investment performance linked to mortgage credit fundamentals. Through its mortgage lending, investment management, and advisory services platforms, the Company operates as a fully integrated mortgage business that originates, manages, and invests in a diversified range of mortgage assets. The Company invests, directly or indirectly, generally on a levered basis across a spectrum of mortgage assets, including residential mortgage loans, Non-Agency RMBS, Agency RMBS, Agency CMBS, MSRs, business purpose and investor loans, including RTLs, and other real estate-related assets.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.